Last week, the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP – the equivalent to the FDA in the United States, recommended approval for vynfinit in the treatment of some platinum resistant ovarian cancers. Vynfinit, developed by Endocyte, targets ovarian cancer cells that have abnormally high levels of the folate receptor. Women with tumors that have too much folate receptor can be identified by a companion diagnostic test, also developed by Enodcyte and recommended by CHMP. The diagnostic tests can be used to identify women with tumors most likely to respond to the new drug. Vynfinit is currently in clinical trials in the United States.
You can read more about the approval here.